• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of biochemjBJ Latest papers and much more!
Biochem J. Oct 1, 1995; 311(Pt 1): 1–16.
PMCID: PMC1136112

The toxicity in vitro of beta-amyloid protein.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (4.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968 Jul;114(512):797–811. [PubMed]
  • Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245–4249. [PMC free article] [PubMed]
  • Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem. 1986 Jun;46(6):1820–1834. [PubMed]
  • Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987 Feb 19;325(6106):733–736. [PubMed]
  • Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990 Jun 1;248(4959):1122–1124. [PubMed]
  • Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 1993 Dec 17;75(6):1039–1042. [PubMed]
  • Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991 Feb 21;349(6311):704–706. [PubMed]
  • Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 1991 Oct 4;254(5028):97–99. [PubMed]
  • Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991 Oct 31;353(6347):844–846. [PubMed]
  • Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992 Aug;1(5):345–347. [PubMed]
  • Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990 Jun 1;248(4959):1124–1126. [PubMed]
  • Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W, Wehnert A, Vegter-Van der Vlis M, Roos RA. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science. 1990 Jun 1;248(4959):1120–1122. [PubMed]
  • Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992 Jun;1(3):218–221. [PubMed]
  • Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992 Dec 17;360(6405):672–674. [PubMed]
  • Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993 Jan 22;259(5094):514–516. [PubMed]
  • Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem. 1994 Jul 1;269(26):17741–17748. [PubMed]
  • Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994 May 27;264(5163):1336–1340. [PubMed]
  • Clements A, Walsh DM, Williams CH, Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. Neurosci Lett. 1993 Oct 14;161(1):17–20. [PubMed]
  • Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985 Mar;17(3):278–282. [PubMed]
  • Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, Tupler RG, Wasco W, Hyman BT, Haines JL, Jenkins BJ, et al. Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet. 1992 Aug;51(2):273–282. [PMC free article] [PubMed]
  • Selkoe DJ. Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. Curr Opin Neurobiol. 1994 Oct;4(5):708–716. [PubMed]
  • Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7247–7251. [PMC free article] [PubMed]
  • Kowall NW, McKee AC, Yankner BA, Beal MF. In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol Aging. 1992 Sep-Oct;13(5):537–542. [PubMed]
  • Pike CJ, Cotman CW. Cultured GABA-immunoreactive neurons are resistant to toxicity induced by beta-amyloid. Neuroscience. 1993 Sep;56(2):269–274. [PubMed]
  • Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993 Apr;13(4):1676–1687. [PubMed]
  • Takadera T, Sakura N, Mohri T, Hashimoto T. Toxic effect of a beta-amyloid peptide (beta 22-35) on the hippocampal neuron and its prevention. Neurosci Lett. 1993 Oct 14;161(1):41–44. [PubMed]
  • May PC, Boggs LN, Fuson KS. Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer's disease amyloid-beta neurotoxicity. J Neurochem. 1993 Dec;61(6):2330–2333. [PubMed]
  • Ueda K, Fukui Y, Kageyama H. Amyloid beta protein-induced neuronal cell death: neurotoxic properties of aggregated amyloid beta protein. Brain Res. 1994 Mar 14;639(2):240–244. [PubMed]
  • Whitson JS, Selkoe DJ, Cotman CW. Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science. 1989 Mar 17;243(4897):1488–1490. [PubMed]
  • Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990 Oct 12;250(4978):279–282. [PubMed]
  • Whitson JS, Glabe CG, Shintani E, Abcar A, Cotman CW. Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci Lett. 1990 Mar 14;110(3):319–324. [PubMed]
  • Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991 Nov 1;563(1-2):311–314. [PubMed]
  • Roher AE, Ball MJ, Bhave SV, Wakade AR. Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem Biophys Res Commun. 1991 Jan 31;174(2):572–579. [PubMed]
  • Koh JY, Yang LL, Cotman CW. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 1990 Nov 19;533(2):315–320. [PubMed]
  • Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992 Feb;12(2):376–389. [PubMed]
  • Copani A, Koh JY, Cotman CW. Beta-amyloid increases neuronal susceptibility to injury by glucose deprivation. Neuroreport. 1991 Dec;2(12):763–765. [PubMed]
  • Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 1993 Sep 3;621(1):35–49. [PubMed]
  • Zhao X, Valantas JA, Vyas S, Duffy LK. Comparative toxicity of amyloid beta-peptide in neuroblastoma cell lines: effects of albumin and physalaemin. Comp Biochem Physiol C. 1993 Sep;106(1):165–170. [PubMed]
  • Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem Biophys Res Commun. 1992 Jul 31;186(2):944–950. [PubMed]
  • Behl C, Davis JB, Klier FG, Schubert D. Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res. 1994 May 9;645(1-2):253–264. [PubMed]
  • Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994 Jun 17;77(6):817–827. [PubMed]
  • Shearman MS, Ragan CI, Iversen LL. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1470–1474. [PMC free article] [PubMed]
  • Zhang Z, Drzewiecki GJ, Hom JT, May PC, Hyslop PA. Human cortical neuronal (HCN) cell lines: a model for amyloid beta neurotoxicity. Neurosci Lett. 1994 Aug 15;177(1-2):162–164. [PubMed]
  • Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol. 1994 Mar;45(3):373–379. [PubMed]
  • Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem. 1995 Jan;64(1):253–265. [PubMed]
  • Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol. 1991 Aug 14;207(4):367–368. [PubMed]
  • Busciglio J, Lorenzo A, Yankner BA. Methodological variables in the assessment of beta amyloid neurotoxicity. Neurobiol Aging. 1992 Sep-Oct;13(5):609–612. [PubMed]
  • Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem. 1992 Jan 5;267(1):546–554. [PubMed]
  • Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol. 1991 Mar 5;218(1):149–163. [PubMed]
  • Halverson K, Fraser PE, Kirschner DA, Lansbury PT., Jr Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry. 1990 Mar 20;29(11):2639–2644. [PubMed]
  • Barrow CJ, Yasuda A, Kenny PT, Zagorski MG. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol. 1992 Jun 20;225(4):1075–1093. [PubMed]
  • Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Human and rodent sequence analogs of Alzheimer's amyloid beta A4 share similar properties and can be solubilized in buffers of pH 7.4. Eur J Biochem. 1991 Oct 1;201(1):61–69. [PubMed]
  • Glenner GG. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980 Jun 5;302(23):1283–1292. [PubMed]
  • Merz PA, Wisniewski HM, Somerville RA, Bobin SA, Masters CL, Iqbal K. Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol. 1983;60(1-2):113–124. [PubMed]
  • Kirschner DA, Abraham C, Selkoe DJ. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci U S A. 1986 Jan;83(2):503–507. [PMC free article] [PubMed]
  • Geddes AJ, Parker KD, Atkins ED, Beighton E. "Cross-beta" conformation in proteins. J Mol Biol. 1968 Mar 14;32(2):343–358. [PubMed]
  • Klapper MH. The independent distribution of amino acid near neighbor pairs into polypeptides. Biochem Biophys Res Commun. 1977 Oct 10;78(3):1018–1024. [PubMed]
  • Barrow CJ, Zagorski MG. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science. 1991 Jul 12;253(5016):179–182. [PubMed]
  • Zagorski MG, Barrow CJ. NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix----beta-sheet conversion for a homologous, 28-residue, N-terminal fragment. Biochemistry. 1992 Jun 23;31(24):5621–5631. [PubMed]
  • Talafous J, Marcinowski KJ, Klopman G, Zagorski MG. Solution structure of residues 1-28 of the amyloid beta-peptide. Biochemistry. 1994 Jun 28;33(25):7788–7796. [PubMed]
  • Kirschner DA, Inouye H, Duffy LK, Sinclair A, Lind M, Selkoe DJ. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6953–6957. [PMC free article] [PubMed]
  • Gorevic PD, Castano EM, Sarma R, Frangione B. Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic x-ray diffraction pattern. Biochem Biophys Res Commun. 1987 Sep 15;147(2):854–862. [PubMed]
  • Lee JP, Stimson ER, Ghilardi JR, Mantyh PW, Lu YA, Felix AM, Llanos W, Behbin A, Cummings M, Van Criekinge M, et al. 1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. Biochemistry. 1995 Apr 18;34(15):5191–5200. [PubMed]
  • Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J. 1994 Sep;67(3):1216–1228. [PMC free article] [PubMed]
  • Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol. 1992 Nov 20;228(2):460–473. [PubMed]
  • Fraser PE, McLachlan DR, Surewicz WK, Mizzen CA, Snow AD, Nguyen JT, Kirschner DA. Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. J Mol Biol. 1994 Nov 18;244(1):64–73. [PubMed]
  • Spencer RG, Halverson KJ, Auger M, McDermott AE, Griffin RG, Lansbury PT., Jr An unusual peptide conformation may precipitate amyloid formation in Alzheimer's disease: application of solid-state NMR to the determination of protein secondary structure. Biochemistry. 1991 Oct 29;30(43):10382–10387. [PubMed]
  • Soto C, Castaño EM, Frangione B, Inestrosa NC. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem. 1995 Feb 17;270(7):3063–3067. [PubMed]
  • Wood SJ, Wetzel R, Martin JD, Hurle MR. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry. 1995 Jan 24;34(3):724–730. [PubMed]
  • LeVine H., 3rd Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993 Mar;2(3):404–410. [PMC free article] [PubMed]
  • Tomski SJ, Murphy RM. Kinetics of aggregation of synthetic beta-amyloid peptide. Arch Biochem Biophys. 1992 May 1;294(2):630–638. [PubMed]
  • Shen CL, Scott GL, Merchant F, Murphy RM. Light scattering analysis of fibril growth from the amino-terminal fragment beta(1-28) of beta-amyloid peptide. Biophys J. 1993 Dec;65(6):2383–2395. [PMC free article] [PubMed]
  • Jarrett JT, Berger EP, Lansbury PT., Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993 May 11;32(18):4693–4697. [PubMed]
  • Jarrett JT, Lansbury PT., Jr Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry. 1992 Dec 15;31(49):12345–12352. [PubMed]
  • Lansbury PT., Jr In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry. 1992 Aug 4;31(30):6865–6870. [PubMed]
  • Fraser PE, Nguyen JT, Surewicz WK, Kirschner DA. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys J. 1991 Nov;60(5):1190–1201. [PMC free article] [PubMed]
  • Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem. 1989 Aug;37(8):1273–1281. [PubMed]
  • Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4766–4770. [PMC free article] [PubMed]
  • Jarrett JT, Lansbury PT., Jr Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993 Jun 18;73(6):1055–1058. [PubMed]
  • Lansbury PT., Jr In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry. 1992 Aug 4;31(30):6865–6870. [PubMed]
  • Come JH, Fraser PE, Lansbury PT., Jr A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5959–5963. [PMC free article] [PubMed]
  • Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol. 1993 Nov;52(6):594–600. [PubMed]
  • Ladror US, Snyder SW, Wang GT, Holzman TF, Krafft GA. Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D. J Biol Chem. 1994 Jul 15;269(28):18422–18428. [PubMed]
  • Joachim CL, Duffy LK, Morris JH, Selkoe DJ. Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging. Brain Res. 1988 Nov 22;474(1):100–111. [PubMed]
  • Prelli F, Castaño E, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem. 1988 Aug;51(2):648–651. [PubMed]
  • Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10836–10840. [PMC free article] [PubMed]
  • Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994 Jul;13(1):45–53. [PubMed]
  • Terzi E, Hölzemann G, Seelig J. Alzheimer beta-amyloid peptide 25-35: electrostatic interactions with phospholipid membranes. Biochemistry. 1994 Jun 14;33(23):7434–7441. [PubMed]
  • Kozlowski MR, Spanoyannis A, Manly SP, Fidel SA, Neve RL. The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding. J Neurosci. 1992 May;12(5):1679–1687. [PubMed]
  • Candy JM, Oakley AE, Klinowski J, Carpenter TA, Perry RH, Atack JR, Perry EK, Blessed G, Fairbairn A, Edwardson JA. Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet. 1986 Feb 15;1(8477):354–357. [PubMed]
  • Kawahara M, Muramoto K, Kobayashi K, Mori H, Kuroda Y. Aluminum promotes the aggregation of Alzheimer's amyloid beta-protein in vitro. Biochem Biophys Res Commun. 1994 Jan 28;198(2):531–535. [PubMed]
  • Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem. 1993 Sep;61(3):1171–1174. [PubMed]
  • Candy JM, Oakley AE, Edwardson JA. Amorphous aluminosilicates promote nucleation of amyloid beta protein and tachykinins. Biochem Soc Trans. 1993 Feb;21(1):53S–53S. [PubMed]
  • Bush AI, Pettingell WH, Jr, Paradis MD, Tanzi RE. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem. 1994 Apr 22;269(16):12152–12158. [PubMed]
  • Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science. 1994 Sep 2;265(5177):1464–1467. [PubMed]
  • Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992 Feb 3;135(2):235–238. [PubMed]
  • Clemens JA, Stephenson DT. Implants containing beta-amyloid protein are not neurotoxic to young and old rat brain. Neurobiol Aging. 1992 Sep-Oct;13(5):581–586. [PubMed]
  • Wisniewski T, Ghiso J, Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1247–1254. [PubMed]
  • Yamada T, Sasaki H, Furuya H, Miyata T, Goto I, Sakaki Y. Complementary DNA for the mouse homolog of the human amyloid beta protein precursor. Biochem Biophys Res Commun. 1987 Dec 16;149(2):665–671. [PubMed]
  • Shivers BD, Hilbich C, Multhaup G, Salbaum M, Beyreuther K, Seeburg PH. Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. EMBO J. 1988 May;7(5):1365–1370. [PMC free article] [PubMed]
  • Lannfelt L, Folkesson R, Mohammed AH, Winblad B, Hellgren D, Duff K, Hardy J. Alzheimer's disease: molecular genetics and transgenic animal models. Behav Brain Res. 1993 Nov 30;57(2):207–213. [PubMed]
  • Otvos L, Jr, Szendrei GI, Lee VM, Mantsch HH. Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. Eur J Biochem. 1993 Jan 15;211(1-2):249–257. [PubMed]
  • Dyrks T, Dyrks E, Masters CL, Beyreuther K. Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett. 1993 Jun 14;324(2):231–236. [PubMed]
  • Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K. Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem. 1992 Sep 5;267(25):18210–18217. [PubMed]
  • Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3270–3274. [PMC free article] [PubMed]
  • Butterfield DA, Hensley K, Harris M, Mattson M, Carney J. beta-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer's disease. Biochem Biophys Res Commun. 1994 Apr 29;200(2):710–715. [PubMed]
  • Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zürcher-Neely HA, Heinrikson RL, Ball MJ, et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem. 1993 Feb 15;268(5):3072–3083. [PubMed]
  • Fabian H, Szendrei GI, Mantsch HH, Greenberg BD, Otvös L., Jr Synthetic post-translationally modified human A beta peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. Eur J Biochem. 1994 May 1;221(3):959–964. [PubMed]
  • Vyas SB, Duffy LK. Stabilization of secondary structure of Alzheimer beta-protein by aluminum(III) ions and D-Asp substitutions. Biochem Biophys Res Commun. 1995 Jan 17;206(2):718–723. [PubMed]
  • Tomiyama T, Asano S, Furiya Y, Shirasawa T, Endo N, Mori H. Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. J Biol Chem. 1994 Apr 8;269(14):10205–10208. [PubMed]
  • Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science. 1981 Jan 30;211(4481):491–493. [PubMed]
  • Colaco CA, Harrington CR. Glycation: a pathological modification in neuropathies?: a hypothesis. Neuroreport. 1994 Apr 14;5(8):859–861. [PubMed]
  • Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5710–5714. [PMC free article] [PubMed]
  • Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T, Horiuchi S. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport. 1995 Apr 19;6(6):866–868. [PubMed]
  • Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991 Dec;5(15):3071–3077. [PubMed]
  • Ikura K, Takahata K, Sasaki R. Cross-linking of a synthetic partial-length (1-28) peptide of the Alzheimer beta/A4 amyloid protein by transglutaminase. FEBS Lett. 1993 Jul 12;326(1-3):109–111. [PubMed]
  • Rasmussen LK, Sørensen ES, Petersen TE, Gliemann J, Jensen PH. Identification of glutamine and lysine residues in Alzheimer amyloid beta A4 peptide responsible for transglutaminase-catalysed homopolymerization and cross-linking to alpha 2M receptor. FEBS Lett. 1994 Jan 31;338(2):161–166. [PubMed]
  • Dudek SM, Johnson GV. Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res. 1994 Jul 18;651(1-2):129–133. [PubMed]
  • Perlmutter DH, Pierce JA. The alpha 1-antitrypsin gene and emphysema. Am J Physiol. 1989 Oct;257(4 Pt 1):L147–L162. [PubMed]
  • Joslin G, Krause JE, Hershey AD, Adams SP, Fallon RJ, Perlmutter DH. Amyloid-beta peptide, substance P, and bombesin bind to the serpin-enzyme complex receptor. J Biol Chem. 1991 Nov 15;266(32):21897–21902. [PubMed]
  • Cheung NS, Small DH, Livett BG. An amyloid peptide, beta A4 25-35, mimics the function of substance P on modulation of nicotine-evoked secretion and desensitization in cultured bovine adrenal chromaffin cells. J Neurochem. 1993 Mar;60(3):1163–1166. [PubMed]
  • Knauer MF, Soreghan B, Burdick D, Kosmoski J, Glabe CG. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7437–7441. [PMC free article] [PubMed]
  • Mattson MP, Rydel RE. beta-Amyloid precursor protein and Alzheimer's disease: the peptide plot thickens. Neurobiol Aging. 1992 Sep-Oct;13(5):617–621. [PubMed]
  • Mattson MP, Barger SW, Cheng B, Lieberburg I, Smith-Swintosky VL, Rydel RE. beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci. 1993 Oct;16(10):409–414. [PubMed]
  • Watt JA, Pike CJ, Walencewicz-Wasserman AJ, Cotman CW. Ultrastructural analysis of beta-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res. 1994 Oct 24;661(1-2):147–156. [PubMed]
  • Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 1994 Apr 21;368(6473):756–760. [PubMed]
  • Mattson MP, Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 1995 Apr 3;676(1):219–224. [PubMed]
  • Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F. Neurotoxicity of a prion protein fragment. Nature. 1993 Apr 8;362(6420):543–546. [PubMed]
  • Blass JP, Gibson GE. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev Neurol (Paris) 1991;147(6-7):513–525. [PubMed]
  • Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7951–7955. [PMC free article] [PubMed]
  • SLATER TF, SAWYER B, STRAEULI U. STUDIES ON SUCCINATE-TETRAZOLIUM REDUCTASE SYSTEMS. III. POINTS OF COUPLING OF FOUR DIFFERENT TETRAZOLIUM SALTS. Biochim Biophys Acta. 1963 Nov 8;77:383–393. [PubMed]
  • Altman FP. Tetrazolium salts and formazans. Prog Histochem Cytochem. 1976;9(3):1–56. [PubMed]
  • Nikkhah G, Tonn JC, Hoffmann O, Kraemer HP, Darling JL, Schönmayr R, Schachenmayr W. The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I: Evaluation of test-specific variables. J Neurooncol. 1992 May;13(1):1–11. [PubMed]
  • Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993 Jun;303(2):474–482. [PubMed]
  • Hawtin SR, Dobbins AC, Tailor VJ, Shearman MS. Beta-amyloid inhibition of MTT reduction is not mimicked by inhibitors of mitochondrial respiration. Biochem Soc Trans. 1995 Feb;23(1):56S–56S. [PubMed]
  • Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):567–571. [PMC free article] [PubMed]
  • Arispe N, Pollard HB, Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10573–10577. [PMC free article] [PubMed]
  • Mirzabekov T, Lin MC, Yuan WL, Marshall PJ, Carman M, Tomaselli K, Lieberburg I, Kagan BL. Channel formation in planar lipid bilayers by a neurotoxic fragment of the beta-amyloid peptide. Biochem Biophys Res Commun. 1994 Jul 29;202(2):1142–1148. [PubMed]
  • Simmons MA, Schneider CR. Amyloid beta peptides act directly on single neurons. Neurosci Lett. 1993 Feb 19;150(2):133–136. [PubMed]
  • Carette B, Poulain P, Delacourte A. Electrophysiological effects of 25-35 amyloid-beta-protein on guinea-pig lateral septal neurons. Neurosci Lett. 1993 Mar 5;151(1):111–114. [PubMed]
  • Davidson RM, Shajenko L, Donta TS. Amyloid beta-peptide (A beta P) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells. Brain Res. 1994 Apr 18;643(1-2):324–327. [PubMed]
  • Furukawa K, Abe Y, Akaike N. Amyloid beta protein-induced irreversible current in rat cortical neurones. Neuroreport. 1994 Oct 27;5(16):2016–2018. [PubMed]
  • Hartmann H, Eckert A, Müller WE. Apolipoprotein E and cholesterol affect neuronal calcium signalling: the possible relationship to beta-amyloid neurotoxicity. Biochem Biophys Res Commun. 1994 May 16;200(3):1185–1192. [PubMed]
  • Busciglio J, Yeh J, Yankner BA. beta-Amyloid neurotoxicity in human cortical culture is not mediated by excitotoxins. J Neurochem. 1993 Oct;61(4):1565–1568. [PubMed]
  • Weiss JH, Pike CJ, Cotman CW. Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J Neurochem. 1994 Jan;62(1):372–375. [PubMed]
  • Copani A, Bruno V, Battaglia G, Leanza G, Pellitteri R, Russo A, Stanzani S, Nicoletti F. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol Pharmacol. 1995 May;47(5):890–897. [PubMed]
  • Pike CJ, Cotman CW. Calretinin-immunoreactive neurons are resistant to beta-amyloid toxicity in vitro. Brain Res. 1995 Feb 13;671(2):293–298. [PubMed]
  • Durell SR, Guy HR, Arispe N, Rojas E, Pollard HB. Theoretical models of the ion channel structure of amyloid beta-protein. Biophys J. 1994 Dec;67(6):2137–2145. [PMC free article] [PubMed]
  • Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci. 1993 Nov;16(11):439–444. [PubMed]
  • Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993 Oct 29;262(5134):689–695. [PubMed]
  • Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med. 1992 Jun;119(6):598–620. [PubMed]
  • Volicer L, Crino PB. Involvement of free radicals in dementia of the Alzheimer type: a hypothesis. Neurobiol Aging. 1990 Sep-Oct;11(5):567–571. [PubMed]
  • Friedlich AL, Butcher LL. Involvement of free oxygen radicals in beta-amyloidosis: an hypothesis. Neurobiol Aging. 1994 Jul-Aug;15(4):443–455. [PubMed]
  • Groner Y, Elroy-Stein O, Bernstein Y, Dafni N, Levanon D, Danciger E, Neer A. Molecular genetics of Down's syndrome: overexpression of transfected human Cu/Zn-superoxide dismutase gene and the consequent physiological changes. Cold Spring Harb Symp Quant Biol. 1986;51(Pt 1):381–393. [PubMed]
  • Elroy-Stein O, Bernstein Y, Groner Y. Overproduction of human Cu/Zn-superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. EMBO J. 1986 Mar;5(3):615–622. [PMC free article] [PubMed]
  • Goodman Y, Steiner MR, Steiner SM, Mattson MP. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid beta-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res. 1994 Aug 15;654(1):171–176. [PubMed]
  • Burdon RH, Gill V, Rice-Evans C. Reduction of a tetrazolium salt and superoxide generation in human tumor cells (HeLa). Free Radic Res Commun. 1993;18(6):369–380. [PubMed]
  • Lockhart BP, Benicourt C, Junien JL, Privat A. Inhibitors of free radical formation fail to attenuate direct beta-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J Neurosci Res. 1994 Nov 1;39(4):494–505. [PubMed]
  • Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, Getzoff ED, Hu P, Herzfeldt B, Roos RP, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993 Aug 20;261(5124):1047–1051. [PubMed]
  • Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7789–7793. [PMC free article] [PubMed]
  • Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995 Apr;14(4):879–888. [PubMed]
  • Forloni G, Chiesa R, Smiroldo S, Verga L, Salmona M, Tagliavini F, Angeretti N. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport. 1993 May;4(5):523–526. [PubMed]
  • Whittemore ER, Loo DT, Cotman CW. Exposure to hydrogen peroxide induces cell death via apoptosis in cultured rat cortical neurons. Neuroreport. 1994 Jul 21;5(12):1485–1488. [PubMed]
  • Rothstein JD, Bristol LA, Hosler B, Brown RH, Jr, Kuncl RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4155–4159. [PMC free article] [PubMed]
  • Troy CM, Shelanski ML. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6384–6387. [PMC free article] [PubMed]
  • Greenlund LJ, Deckwerth TL, Johnson EM., Jr Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron. 1995 Feb;14(2):303–315. [PubMed]
  • Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport. 1994 Dec 20;5(18):2529–2533. [PubMed]
  • Mah SP, Zhong LT, Liu Y, Roghani A, Edwards RH, Bredesen DE. The protooncogene bcl-2 inhibits apoptosis in PC12 cells. J Neurochem. 1993 Mar;60(3):1183–1186. [PubMed]
  • Zhong LT, Sarafian T, Kane DJ, Charles AC, Mah SP, Edwards RH, Bredesen DE. bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4533–4537. [PMC free article] [PubMed]
  • Behl C, Hovey L, 3rd, Krajewski S, Schubert D, Reed JC. BCL-2 prevents killing of neuronal cells by glutamate but not by amyloid beta protein. Biochem Biophys Res Commun. 1993 Dec 15;197(2):949–956. [PubMed]
  • McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989 Dec 15;107(1-3):341–346. [PubMed]
  • Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016–10020. [PMC free article] [PubMed]
  • Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol. 1994 May 15;152(10):5050–5059. [PubMed]
  • Schultz J, Schaller J, McKinley M, Bradt B, Cooper N, May P, Rogers J. Enhanced cytotoxicity of amyloid beta-peptide by a complement dependent mechanism. Neurosci Lett. 1994 Jul 4;175(1-2):99–102. [PubMed]
  • Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME, Mantyh PW. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5462–5466. [PMC free article] [PubMed]
  • Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977–1981. [PMC free article] [PubMed]
  • Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622–630. [PubMed]
  • Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8098–8102. [PMC free article] [PubMed]
  • Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun. 1993 Apr 30;192(2):359–365. [PubMed]
  • Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991 Feb 8;541(1):163–166. [PubMed]
  • Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9649–9653. [PMC free article] [PubMed]
  • Berr C, Hauw JJ, Delaère P, Duyckaerts C, Amouyel P. Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease. Neurosci Lett. 1994 Sep 12;178(2):221–224. [PubMed]
  • Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994 Jun;7(2):180–184. [PubMed]
  • Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994 Aug;94(2):860–869. [PMC free article] [PubMed]
  • Ma J, Yee A, Brewer HB, Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994 Nov 3;372(6501):92–94. [PubMed]
  • Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995 Mar 1;306(Pt 2):599–604. [PMC free article] [PubMed]
  • LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994 Sep 23;269(38):23403–23406. [PubMed]
  • LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem. 1995 Apr 21;270(16):9039–9042. [PubMed]
  • Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT., Jr Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):763–767. [PMC free article] [PubMed]
  • Whitson JS, Mims MP, Strittmatter WJ, Yamaki T, Morrisett JD, Appel SH. Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. Biochem Biophys Res Commun. 1994 Feb 28;199(1):163–170. [PubMed]
  • Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J. 1993 Jul 1;293(Pt 1):27–30. [PMC free article] [PubMed]
  • Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem. 1995 Mar 31;270(13):7563–7567. [PubMed]
  • Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T, Tomita M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 1992;83(3):260–264. [PubMed]
  • Golabek A, Marques MA, Lalowski M, Wisniewski T. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett. 1995 May 19;191(1-2):79–82. [PubMed]
  • Wisniewski T, Ghiso J, Frangione B. Alzheimer's disease and soluble A beta. Neurobiol Aging. 1994 Mar-Apr;15(2):143–152. [PubMed]
  • Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8368–8372. [PMC free article] [PubMed]
  • Uéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11282–11286. [PMC free article] [PubMed]
  • Brookes AJ, St Clair D. Synuclein proteins and Alzheimer's disease. Trends Neurosci. 1994 Oct;17(10):404–405. [PubMed]
  • Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995 Feb;14(2):467–475. [PubMed]
  • Han H, Weinreb PH, Lansbury PT., Jr The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol. 1995 Mar;2(3):163–169. [PubMed]
  • Snow AD, Wight TN. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging. 1989 Sep-Oct;10(5):481–497. [PubMed]
  • Brunden KR, Richter-Cook NJ, Chaturvedi N, Frederickson RC. pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans. J Neurochem. 1993 Dec;61(6):2147–2154. [PubMed]
  • Leveugle B, Scanameo A, Ding W, Fillit H. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport. 1994 Jun 27;5(11):1389–1392. [PubMed]
  • McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R. Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J. 1988 Dec 15;256(3):775–783. [PMC free article] [PubMed]
  • Fraser PE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem. 1992 Oct;59(4):1531–1540. [PubMed]
  • Fraser PE, Lévesque L, McLachlan DR. Biochemistry of Alzheimer's disease amyloid plaques. Clin Biochem. 1993 Oct;26(5):339–349. [PubMed]
  • Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells. Neurosci Lett. 1995 Jan 23;184(2):113–116. [PubMed]
  • Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol. 1993 Feb;67(2):643–650. [PMC free article] [PubMed]
  • Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem. 1995 Apr 21;270(16):9564–9570. [PubMed]
  • Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med. 1995 Feb;1(2):143–148. [PubMed]
  • Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. 1994 Aug;151(8):1105–1113. [PubMed]
  • Cummings BJ, Su JH, Geddes JW, Van Nostrand WE, Wagner SL, Cunningham DD, Cotman CW. Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease. Neuroscience. 1992 Jun;48(4):763–777. [PubMed]
  • Strittmatter WJ, Huang DY, Bhasin R, Roses AD, Goldgaber D. Avid binding of beta A amyloid peptide to its own precursor. Exp Neurol. 1993 Aug;122(2):327–334. [PubMed]
  • Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP. Structure of pentameric human serum amyloid P component. Nature. 1994 Jan 27;367(6461):338–345. [PubMed]
  • Hamazaki H. Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer's beta-amyloid peptide. J Biol Chem. 1995 May 5;270(18):10392–10394. [PubMed]
  • Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4299–4303. [PMC free article] [PubMed]
  • Abraham CR, Shirahama T, Potter H. Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin. Neurobiol Aging. 1990 Mar-Apr;11(2):123–129. [PubMed]
  • Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem. 1993 Jul;61(1):298–305. [PubMed]
  • Kobayashi T, Abe K, Saito H, Nishiyama N. Effect of alpha 1-antichymotrypsin on the toxicity of beta-amyloid fragment 25-40 in rat primary cultured neurons. Neurosci Lett. 1994 May 19;172(1-2):147–150. [PubMed]
  • Eriksson S, Janciauskiene S, Lannfelt L. Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2313–2317. [PMC free article] [PubMed]
  • Kalaria RN, Perry G. Amyloid P component and other acute-phase proteins associated with cerebellar A beta-deposits in Alzheimer's disease. Brain Res. 1993 Dec 17;631(1):151–155. [PubMed]
  • Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 1989;77(6):569–575. [PubMed]
  • Ishii T, Haga S. Complements, microglial cells and amyloid fibril formation. Res Immunol. 1992 Jul-Aug;143(6):614–616. [PubMed]
  • Webster S, O'Barr S, Rogers J. Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res. 1994 Nov 1;39(4):448–456. [PubMed]
  • Davis JB, McMurray HF, Schubert D. The amyloid beta-protein of Alzheimer's disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun. 1992 Dec 15;189(2):1096–1100. [PubMed]
  • Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer beta amyloid peptide. Biochem Biophys Res Commun. 1994 Mar 15;199(2):984–991. [PubMed]
  • Meda L, Cassatella MA, Szendrei GI, Otvos L, Jr, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995 Apr 13;374(6523):647–650. [PubMed]
  • Araujo DM, Cotman CW. Beta-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res. 1992 Jan 8;569(1):141–145. [PubMed]
  • Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7606–7610. [PMC free article] [PubMed]
  • Quon D, Catalano R, Cordell B. Fibroblast growth factor induces beta-amyloid precursor mRNA in glial but not neuronal cultured cells. Biochem Biophys Res Commun. 1990 Feb 28;167(1):96–102. [PubMed]
  • Halvorson C, Hays A, Kraabel B, Wu R, Wudl F, Heeger AJ. A 160-femtosecond optical image processor based on a conjugated polymer. Science. 1994 Aug 26;265(5176):1215–1216. [PubMed]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links